Journal of International Oncology ›› 2017, Vol. 44 ›› Issue (8): 689-692.doi: 10.3760/cma.j.issn.1673422X.2017.09.012

Previous Articles     Next Articles

Molecular targeted therapy in glioblastoma

Nan Yang, Zhong Yue   

  1. Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin 300052, China
  • Online:2017-09-08 Published:2017-10-31
  • Contact: Nan Yang E-mail:2011nanyang@163.com
  • Supported by:

     National Natural Science Fundation of China (81572490)

Abstract: Glioblastomas is the most common malignant primary brain tumors and the prognosis is very poor. With the development of tumor molecular biology, molecular targeted therapy for glioblastomas has become an integral part of its comprehensive treatment. Targeted therapy drugs of glioblastomas are emerging, including tyrosine kinase inhibitors, histone deacetylase inhibitors, phosphatidylinositol 3kinase inhibitors, hypoxia inducible factor1α inhibitors, sodiumpotassium pump inhibitors, et al. With the development of new molecular targeted therapy, more effective or even treatment measures of glioblastomas might be found, which can provide a new approach for the individualized treatment of glioblastomas.【Key words】

Key words: Glioma, Targeted therapy